HIK.L लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 21:05):

Stats
आज की मात्रा	6.26M
औसत मात्रा	622 167
बाजार मूल्य	4.35B
EPS	£0 ( 2024-02-22 )
Last Dividend	£25.00 ( 2023-08-10 )
Next Dividend	£0 ( N/A )
P/E	28.82
ATR14	£1.822 (0.09%)

मात्रा सहसंबंध

लंबा: 0.20 (neutral)

छोटा: -0.92 (very strong negative)

Signal:(46.114) Neutral

Hikma Pharmaceuticals PLC सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Hikma Pharmaceuticals PLC सहसंबंध - मुद्रा/वस्त्र

-0.61
( weak negative )

-0.38
( neutral )

0.50
( neutral )

0.21
( neutral )

0.25
( neutral )

-0.26
( neutral )

Hikma Pharmaceuticals PLC वित्तीय

Annual	2023
राजस्व:	£2.88B
सकल लाभ:	£1.39B (48.35 %)
EPS:	£0.860

FY	2023
राजस्व:	£2.88B
सकल लाभ:	£1.39B (48.35 %)
EPS:	£0.860

FY	2023
राजस्व:	£0
सकल लाभ:	£0 (0.00 %)
EPS:	£0

FY	2022
राजस्व:	£2.52B
सकल लाभ:	£1.27B (50.26 %)
EPS:	£0.840

Financial Reports:

No articles found.

Hikma Pharmaceuticals PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£16.00 (N/A)	£0 (N/A)	£29.52 (N/A)	£0 (N/A)	£25.00 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

Hikma Pharmaceuticals PLC Dividend Information - Dividend Knight

Dividend Sustainability Score: 9.93 - good (99.32%) | Divividend Growth Potential Score: 3.83 - Decrease likely (23.40%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£0.500	2006-04-26
Last Dividend	£25.00	2023-08-10
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	36	--
Total Paid Out	£347.38	--
Avg. Dividend % Per Year	1.60%	--
Score	4.06	--
Div. Sustainability Score	9.93
Div.Growth Potential Score	3.83
Div. Directional Score	6.88	--

Next Divdend (Est)
(2024-06-25)

£25.96 Estimate 7.54 %

Dividend Stability

0.30 Poor

Dividend Score

4.06

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2006	£0	0.00%
2007	£0	0.00%
2008	£0	0.00%
2009	£0	0.00%
2010	£0	0.00%
2011	£0	0.00%
2012	£0	0.00%
2013	£0	0.00%
2014	£0	0.00%
2015	£0	0.00%
2016	£0	0.00%
2017	£0	0.00%
2018	£25.40	1.92%
2019	£34.00	1.99%
2020	£36.22	1.82%
2021	£37.70	1.47%
2022	£42.00	1.92%
2023	£54.52	3.36%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SEPL.L	Dividend Royal	2023-08-16	Bi-Monthly	11	9.82%
IBM.L	Dividend King	2023-08-09	Quarterly	17	3.30%
BGLF.L	Dividend King	2023-08-03	Quarterly	9	6.38%
WWH.L	Dividend Junior	2023-06-08	Semi-Annually	29	0.48%
NICL.L	Dividend King	2023-08-03	Semi-Annually	32	1.45%
EKF.L	Ex Dividend Knight	2023-11-02	Annually	5	0.73%
SPX.L	Dividend Knight	2023-10-12	Semi-Annually	32	0.67%
JARA.L	Dividend Knight	2023-08-03	Quarterly	5	2.54%
BSIF.L	Dividend Knight	2023-08-17	Quarterly	11	3.73%
PMI.L	Dividend King	2023-07-06	Semi-Annually	8	4.24%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0661	1.500	8.68	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0406	1.200	8.65	10.00	[0 - 0.3]
returnOnEquityTTM	0.0866	1.500	-0.149	-0.223	[0.1 - 1]
payoutRatioTTM	0.721	-1.000	2.79	-2.79	[0 - 1]
currentRatioTTM	1.568	0.800	7.16	5.73	[1 - 3]
quickRatioTTM	0.831	0.800	9.82	7.85	[0.8 - 2.5]
cashRatioTTM	0.153	1.500	-0.261	-0.391	[0.2 - 2]
debtRatioTTM	0.254	-1.500	5.76	-8.64	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	2.68	2.00	9.11	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.939	2.00	9.03	10.00	[0 - 20]
debtEquityRatioTTM	0.542	-1.500	7.83	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.489	1.000	5.18	5.18	[0.2 - 0.8]
operatingProfitMarginTTM	0.215	1.000	7.69	7.69	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.510	1.000	8.28	8.28	[0.2 - 2]
assetTurnoverTTM	0.614	0.800	9.24	7.39	[0.5 - 2]
Total Score				9.93

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	29.31	1.000	7.14	0	[1 - 100]
returnOnEquityTTM	0.0866	2.50	-0.0956	-0.223	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.939	2.00	9.35	10.00	[0 - 30]
dividendYielPercentageTTM	2.15	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.68	2.00	9.11	10.00	[0 - 30]
payoutRatioTTM	0.721	1.500	2.79	-2.79	[0 - 1]
pegRatioTTM	-119.14	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.211	1.000	7.21	0	[0.1 - 0.5]
Total Score				3.83

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.